Subscribe
shutterstock_1349461187_pavel_kapysh
Pavel Kapysh / Shutterstock.com
5 October 2021GenericsAlex Baldwin

NJ judge invalidates Sun patent in BromSite suit

A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Lupin and Sun settle Bromsite patent suit after ruling
10 February 2022   Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Generics
Lupin and Sun settle Bromsite patent suit after ruling
10 February 2022   Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More on this story

Generics
Lupin and Sun settle Bromsite patent suit after ruling
10 February 2022   Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?